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Abstracts / Biol Blood Marrow Transplant 21 (2015) S25eS29 S27syngeneic mice. Administration of PSL signiﬁcantly reduced
T cell inﬁltration in the granulosa cell layers and restored
the serum levels of AMH (Fig. 1), numbers of oocytes (Fig.
2), and fertility (Fig. 3) in allogeneic mice.
Conclusion: Our results demonstrate for the ﬁrst time that
GVHD induces infertility by targeting the granulosa cells in
the ovaries and GVHD prevention could preserve ovarian
functions. These results have important clinical implications
in young female transplant recipients with nonmalignant
diseases, whereminimally toxic chemotherapies prior to SCT
and conditioning regimen were used.3
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A relationship between the microbiota and GVHD has
long been suspected but is still not well understood.
We treated healthy 129S1 mice with either antibiotics (ABX)
that included signiﬁcant activity against anaerobic bacteria
(piperacillin-tazobactam; pip-tazo, imipenem-cilastatin;
imipenem or ones with reduced activity (cefepime, aztreo-
nam). Mice were treated by s.c. injections of each antibiotic
twice a day for two days and stool samples were collected,
followed by 16S rRNA gene ampliﬁcation and sequence
analysis. We found that treatment with pip-tazo andimipe-
nem signiﬁcantly reduced the abundance of anaerobic
Clostridial species and increased that of Enterococcus, while
treatment with cefepime and aztreonam spared ClostridialesFigure 1. Clostridiales eliminating antibiotic imipenem worsens GVHD survival. A) 16
Lethally irradiated 129S1 recipients were transplanted with C57BL/6 T cell depleted bo
treated with imipenem or aztreonam (100 mg/kg, s.c., 3 times a week, from day 10 to
for 4 days before BMT and orally introduced 17 Clostridia isolates from human stool, fo
TCD-BM cells. *, P<0.05.(Figure 1A). We next investigated the effects of ABX treat-
ment in a minor antigen mismatched murine allogeneic BMT
model (C57BL/6 -> 129S1). Recipients were either treated
with imipenem or aztreonam s.c. beginning on day +10 after
BMT. We observed signiﬁcantly worsened GVHD survival in
imipenem-treated recipients (Figure 1B, P<0.01). To further
explore the impact of anaerobic bacteria on GVHD, we
treated recipient mice with an oral combination of ampi-
cillin, clindamycin, vancomycin and metronidazole and
thereafter re-introduced a mixture of 17 Clostridia isolates
derived from human stool previously shown to upregulate
Tregs in the colon of mice. We found that introduction of this
Clostridial mixture to mice before BMT resulted in improved
GVHD survival (Figure 1C, P<0.05). Finally, we evaluated the
impact of ABX treatment on graft-versus-tumor (GVT) ac-
tivity and found that elimination of gut bacteria with pip-
tazo did not alter GVT activity in mouse A20-TGL tumor BMT
model. Together, these results suggest that selection of ABX
that spare anaerobic bacteria may be an effective strategy to
reduce GVHD without impacting on GVT, and that this effect
may be mediated by maintaining Clostridial commensals.
We have also retrospectively examined a cohort of 546
adult patients transplanted at MSKCC from 1992 to 2013 who
received conventional (non-T cell depleted) grafts and
received treatment for peri-transplant fever with empiric
ABX classiﬁed as either including anaerobic coverage or with
reduced anaerobic activity. Of these, 156 patients who
received ABX from both classiﬁcations were excluded, as
were 99 patients exposed to other ABX with anaerobic
coverage not routinely used to treat peri-transplant fever.We
examined the impact of anaerobic coverage in the remaining
291 patients. We found that 60 patients that received ABX
without anaerobic coverage had a signiﬁcantly reduced
incidence of GVHD-related mortality, compared to 231 pa-
tients treated with anaerobe-active ABX (Figure 2, P<0.05).
These results raised the possibility that anaerobic commen-
sals may be protective against GVHD in humans as well as in
murine models.s rRNA sequence analysis after antibiotics treatment in healthy 129S1 mice. B)
ne marrow (TCD-BM) cells with 2  106 C57BL/6 T cells. Recipients were either
day 24). **, P<0.01. C) C57BL/6 recipients were treated with antibiotics cocktail
llowed by lethal irradiation and transfer of allogeneic B10.BR donor T cells with
Figure 2. Association between anaerobic activity of treatment for peri-
transplant fever during allo BMT hospitalization and subsequent GVHD-
related mortality. Patients treated for peri-transplant fever during allo BMT
hospitalization at MSKCC were treated with antibiotics containing signiﬁcant
activity against obligate anaerobes (piperacillin-tazobactam, ticarcillin-clav-
ulanate, imipenem-cilastatin, meropenem) or with antibiotics without sig-
niﬁcant activity against obligate anaerobes (ceftriaxone, ceftazidime, cefepime,
aztreonam).
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Background: Autologous stem cell transplant (ASCT) is the
standard of care for patients (pts) with relapsed/refractory
Hodgkin lymphoma (HL), providing a cure for approximately
50% of pts; however, most pts with risk factors will progress
post-ASCT (Sureda 2005). Brentuximab vedotin comprises anantieCD30 antibody conjugated by a protease-cleavable
linker to a microtubule-disrupting agent, monomethyl auri-
statin E (MMAE), and has an objective response rate of 75% in
relapsed or refractory HL. The AETHERA trial was initiated to
evaluate whether early treatment with brentuximab vedotin
post-ASCT can prevent progression in pts with HL (Clinical-
Trials.gov #NCT01100502).
Methods: The AETHERA trial is a phase 3, randomized,
double-blind, placebo-controlled, multicenter study. After
ASCT, pts received brentuximab vedotin 1.8 mg/kg q3wk or
placebo for up to 16 cycles. Pts with disease progressionwere
to discontinue therapy and could request unblinding; these
pts may have received subsequent brentuximab vedotin on
another clinical trial or on-label in some regions. The primary
endpoint is progression-free survival (PFS) per an indepen-
dent review facility (IRF).
Results: A total of 329 pts were randomized at 78 sites in the
US and Europe. The median age was 32 years (range, 18e76)
and 53% were male. Pts were enrolled in 1 of 3 high-risk
categories: refractory to frontline (FL) therapy: 196 pts (60%),
relapse <12 mos after FL therapy: 107 pts (33%), and relapse
12 mos after FL therapy with extranodal disease: 26 pts
(8%). Response to salvage therapy pre-ASCT was complete
remission: 137 pts (42%), partial remission: 112 pts (34%),
and stable disease: 80 pts (24%). The median number of prior
systemic therapies was 2 (range, 2e8); 47% of pts received
more than 2 prior systemic therapies. Prior to pre-ASCT
salvage therapy, 106 pts (32%) had extranodal involvement
and 87 pts (26%) had B symptoms. Prior to ASCT,110 pts (33%)
were PETenegative, 116 pts (35%) were PET-positive, and PET
status was unknown for 103 pts (31%). All pts had completed
or discontinued study treatment as of August 2013. The
median number of treatment cycles was 15.
Adverse events (AEs) of any grade in >15% of all pts were
peripheral sensory neuropathy (36%), upper respiratory tract
infection (25%), neutropenia (24%), fatigue (21%), cough
(19%), and pyrexia (17%). Grade 3 or higher AEs in 10 pts
were neutropenia (20%), peripheral sensory neuropathy (6%),
thrombocytopenia (3%), and peripheral motor neuropathy
(3%).
The primary results were released on September 29th,
2014. The PFS per IRF for patients who received brentuximab
vedotin was statistically signiﬁcantly improved compared to
patients who received placebo (hazard ratio 0.57; P¼0.001).
Conclusions: Brentuximab vedotin signiﬁcantly improved
the post-ASCT PFS of patients with HL. Complete efﬁcacy and
safety data will be presented at the conference.5
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Background: Hematopoietic stem cell (HSC) gene therapy
has the potential to induce globin production in the RBC
